Sangamo Therapeutics, Inc
ST-503
chronic neuropathic pain
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for ST-503 in chronic neuropathic pain are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Six sites have been activated in the Phase 1/2 STAND study evaluating ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain.”